ArticleGynecologic oncology2025
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03206177 (Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveCarcinosarcoma (CS) is a rare, aggressive malignancy characterized by high rates of extrauterine spread, frequent recurrences, and poor prognosis. Until recently, the standard of care treatment included surgery and chemotherapy given in an adjuvant or metastatic setting. This study assessed safety and tolerability of combining carboplatin(C) and paclitaxel(T) with the TGFb-R1 inhibitor galunisertib (GB).
methodsIn this IRB approved (NCT03206177) feasibility study, eligible patients (pts) included those diagnosed with uterine or ovarian CS for whom treatment with CT is planned. A safety lead of CT plus GB 80 mg days 4-17 on a 28-day cycle, and if no dose-limiting toxicities (DLTs), the full dose of GB 150 mg BID would be used. The primary endpoint was completing 4 cycles of combination therapy without DLT.
results3 patients were enrolled in the safety lead and 21 pts. were treated with CT and GB 150 mg po BID combination for a total of 24 patients. Among them, 81 % had stage III/IV and 54.2 % had measurable disease (MD). No DLTs were reported in the safety lead in. Among the 21 pts. treated at 150 mg po BID 1/21 had a DLT that compromised completion of 4 cycles. Therefore, the combination was deemed feasible. Among the 13 pts. with MD, 31 % had a partial response and 15 % had stable disease. The median progression-free survival (PFS) was 6.6 months (95 % CI: 5.4-10.8 months), and the median overall survival (OS) was 18.9 months (95 % CI: 10.81 -NR). 75 % had ≥ grade 3 treatment-emerged adverse events, the most common was neutropenia (41.7 %).
conclusionsGB with CT was well-tolerated with 1 DLT noted. The study was prematurely stopped when the development of GB was discontinued, but targeting TGFb downstream signaling remains of interest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.